Please login to the form below

Not currently logged in
Email:
Password:

Europe votes for greater clinical trial transparency

European Parliament passes new EU Clinical Trials Regulation

EU flagThe European Parliament has approved new measures to force researchers to make their clinical trial results available, with fines available to deal with non-compliance.

MEPs voted by an overwhelming majority to pass the new EU Clinical Trials Regulation, which will require pharma and academic researchers to post all their European Clinical Trial results – including for negative studies.

The law, which is expected to take effect in 2016, will also facilitate cross-border cooperation on trials – potentially improving efforts to study rare diseases by opening up a greater pool of patients and reducing costs.

The legislation was steered through the Parliament by the UK's Glenis Willmott, who said she was delighted by the backing given by her fellow MEPs.

"It will make trials more transparent, give hope to patients needing new and better treatments, and boost the number of skilled research jobs here in Europe.

"The new law will also offer hope to the millions of people in Europe suffering from rare diseases, by making cross-border trials much easier to conduct. There are simply not enough patients in one country alone to develop new or improved treatments for rare diseases.”

The changes will simplify reporting procedures and empower the European Commission to carry out checks, with fixed deadlines for member states to respond to product application dossiers from clinical trial sponsors.

In a bid to improve trial transparency, detailed summaries - including full clinical study reports – will have to be published in a publicly-accessible EU database, once a decision on marketing authorisation has been taken or the marketing authorisation application has been withdrawn.

European pharma body EFPIA said the adoption of the new Clinical Trials Regulation would “help foster a more harmonised approach to clinical trials in the EU, with a single submission and overall streamlined assessment process”.

It added: “EFPIA also welcomes the legislation's approach to transparency, which respects the need to protect personal patient data and commercially confidential information.”

But the body added it would be critical that the Commission and EMA interpret the law in such as way as to “respect patient privacy, the integrity of regulatory decision-making and incentives for companies to make long-term investments in biomedical research”.

Article by
Dominic Tyer

3rd April 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics